Neurocrine Biosciences, Inc. (NBIX)
153.04
+0.47
(+0.31%)
USD |
NASDAQ |
Aug 24, 16:00
153.04
0.00 (0.00%)
After-Hours: 20:00
Neurocrine Biosciences Net Income (Quarterly) : 144.40M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 144.40M |
| March 31, 2026 | 197.90M |
| December 31, 2025 | 153.70M |
| September 30, 2025 | 209.50M |
| June 30, 2025 | 107.50M |
| March 31, 2025 | 7.90M |
| December 31, 2024 | 103.10M |
| September 30, 2024 | 129.80M |
| June 30, 2024 | 65.00M |
| March 31, 2024 | 43.40M |
| December 31, 2023 | 147.70M |
| September 30, 2023 | 83.10M |
| June 30, 2023 | 95.50M |
| March 31, 2023 | -76.60M |
| December 31, 2022 | 89.00M |
| September 30, 2022 | 68.50M |
| June 30, 2022 | -16.90M |
| March 31, 2022 | 13.90M |
| December 31, 2021 | -7.30M |
| September 30, 2021 | 22.50M |
| June 30, 2021 | 42.30M |
| March 31, 2021 | 32.10M |
| December 31, 2020 | 347.90M |
| September 30, 2020 | -57.60M |
| June 30, 2020 | 79.60M |
| Date | Value |
|---|---|
| March 31, 2020 | 37.40M |
| December 31, 2019 | 34.00M |
| September 30, 2019 | 53.79M |
| June 30, 2019 | 51.34M |
| March 31, 2019 | -102.12M |
| December 31, 2018 | 18.08M |
| September 30, 2018 | 50.76M |
| June 30, 2018 | -5.913M |
| March 31, 2018 | -41.82M |
| December 31, 2017 | 6.894M |
| September 30, 2017 | -11.12M |
| June 30, 2017 | -59.98M |
| March 31, 2017 | -78.33M |
| December 31, 2016 | -44.66M |
| September 30, 2016 | -36.89M |
| June 30, 2016 | -40.28M |
| March 31, 2016 | -19.26M |
| December 31, 2015 | -29.32M |
| September 30, 2015 | -34.44M |
| June 30, 2015 | -23.99M |
| March 31, 2015 | -1.192M |
| December 31, 2014 | -19.44M |
| September 30, 2014 | -15.88M |
| June 30, 2014 | -13.38M |
| March 31, 2014 | -11.84M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Amarin Corp. Plc | -7.664M |
| Liquidia Corp. | 74.72M |
| Incyte Corp. | 585.60M |
| Krystal Biotech, Inc. | 54.77M |
| Halozyme Therapeutics, Inc. | 229.91M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 959.00M |
| Total Expenses (Quarterly) | 814.60M |
| EPS Diluted (Quarterly) | 1.386 |
| Enterprise Value | 15.56B |
| Gross Profit Margin (Quarterly) | 95.87% |
| Profit Margin (Quarterly) | 15.06% |
| Earnings Yield | 4.46% |
| Operating Earnings Yield | 5.09% |
| Normalized Earnings Yield | 4.371 |